SCHEMBL21593334

SCHEMBL21593334

COc1cc(Br)cc2c1C(=O)N(C1CC1)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIK1 P57059 1/20 0.42
SIK2 Q9H0K1 1/20 0.42
SIK3 Q9Y2K2 1/20 0.42
HTR2A P28223 2/20 0.40
HTR2C P28335 2/20 0.40
HTR2B P41595 2/20 0.40
PARP1 P09874 1/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CNR1 P21554 1/20 0.36
KLK7 P49862 1/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
SLC6A4 P31645 1/20 0.35
FKBP1A P62942 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21593335 0.83 MAOA (0.34) SIK1SIK2SIK3PARP1MAOA
SCHEMBL22491205 0.81 SIK2 (0.41) SIK1SIK2SIK3HTR2AHTR2C
SCHEMBL29677167 0.81 SIK2 (0.41) SIK1SIK2SIK3HTR2AHTR2C
SCHEMBL23193791 0.81 SIK2 (0.41) SIK1SIK2SIK3HTR2AHTR2C
SCHEMBL28597676 0.80 MEN1 (0.55) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL25150910 0.80 USP30 (0.42) MEN1KMT2AKDM4EMAPT
SCHEMBL30400063 0.80 USP30 (0.42) MEN1KMT2AKDM4EMAPT
SCHEMBL21591056 0.79 MAOA (0.35) PARP1MAOAMAOB
SCHEMBL21591070 0.79 MAOA (0.35) PARP1CNR1MAOAMAOBSMN1; SMN2
SCHEMBL21593345 0.78 GRM5 (0.42) SIK2MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724431-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND USE THEREOF Beone Medicines I GmbH (CH) 2026-04-15 EP disclosed
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2026-03-26 US disclosed
US-12264156-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases GALAPAGOS NV (BE) 2025-04-01 US disclosed
US-12065443-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases GALAPAGOS NV (BE) 2024-08-20 US disclosed
CN-111433200-B Compounds and pharmaceutical compositions for the treatment of diseases 加拉帕戈斯股份有限公司 2024-03-22 CN disclosed
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-12-22 US disclosed
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-12-22 US disclosed
US-20220340581-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-10-27 US disclosed
US-11339166-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases GALAPAGOS NV (BE) 2022-05-24 US disclosed
US-11339166-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases GALAPAGOS NV (BE) 2022-05-24 US disclosed
EP-3717471-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-01-05 EP disclosed
US-20210101903-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2021-04-08 US disclosed
US-20210101903-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2021-04-08 US disclosed
EP-3717471-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES Galapagos NV (BE) 2020-10-07 EP disclosed
CN-111433200-A Novel compounds and pharmaceutical compositions thereof for the treatment of diseases 加拉帕戈斯股份有限公司 2020-07-17 CN disclosed
WO-2019238424-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2019-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11339166-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases F12, F3, COL1A1 SIK1 3852/4885SIK2 4122/4885SIK3 1967/4885
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF SIK1, CHUK, SIK2 SIK1 1/4885SIK2 3/4885SIK3 5/4885
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES IL1A, TNF, IL6 SIK1 3905/4885SIK2 4381/4885SIK3 3390/4885
US-12264156-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases TNF, IL1A, COL1A1 SIK1 3832/4885SIK2 4373/4885SIK3 3341/4885
US-12065443-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases F12, F3, COL1A1 SIK1 3852/4885SIK2 4122/4885SIK3 1967/4885
US-20220340581-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES F12, F3, COL1A1 SIK1 3852/4885SIK2 4122/4885SIK3 1967/4885
US-20210101903-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES JAK3, IFNG, IL23R SIK1 3947/4885SIK2 4246/4885SIK3 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.